Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.08
−$0.075 · -3.48%
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Previous close
$2.08
−$0.075 · -3.48%
Regular session · ET · Market data may be delayed.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Day range
Current $2.08
52-week range
Current $2.08
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
74
Undervalued
Sentiment
55
Mixed
Risk
65
High Risk
Momentum
32
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions. The company's diverse pipeline features: RAD 204, designed to target PD-L1 for non-small cell lung cancer; RAD 202, aimed at HER2 for breast cancer and other solid tumor types; and two avß6 integrin-targeting agents, RAD 301 (a diagnostic tool for pancreatic ductal adenocarcinoma) and RAD 302 (a therapeutic agent for various cancers). Other significant developments include RAD 101 and RAD 102 for brain metastases, RAD 402 for advanced prostate cancer, and RV01 for multiple solid tumors. To accelerate the clinical progression of its radiopharmaceutical assets, Radiopharm Theranostics maintains a strategic partnership with Lantheus Holdings, Inc.
Day range
Current $2.08
52-week range
Current $2.08
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (AUD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 2.71M AUD | 3.63M AUD | 299.23K AUD | 292.36K AUD | 8.83K AUD |
| Cost of goods sold | 4.81M AUD | 3.59M AUD | — | — | — |
| Gross profit | −2.1M AUD | 39.28K AUD | 299.23K AUD | 292.36K AUD | 8.83K AUD |
| Research and development | — | 27.52M AUD | 17.56M AUD | 13.8M AUD | 4.12M AUD |
| Selling, general, and administrative | 15.86M AUD | 16.53M AUD | 15.22M AUD | 13.02M AUD | 10.85M AUD |
| Operating expenses | 64.73M AUD | 38.21M AUD | 36.92M AUD | 34.8M AUD | 19.93M AUD |
| Interest income | — | 888.2K AUD | 50.48K AUD | 145.04K AUD | — |
| Interest expense | 109.94K AUD | 65.3K AUD | 642.89K AUD | 86.09K AUD | 9.35M AUD |
| Depreciation and amortization | — | 7.33K AUD | 3.13M AUD | 3.3M AUD | 2.98M AUD |
| Operating income | −66.84M AUD | −38.17M AUD | −36.62M AUD | −34.51M AUD | −19.92M AUD |
| Net income | −53.94M AUD | −38.34M AUD | −47.95M AUD | −34.61M AUD | −30.34M AUD |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$6.00
188.46% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
